{"id":8394,"date":"2026-07-17T10:47:57","date_gmt":"2026-07-17T02:47:57","guid":{"rendered":"https:\/\/witology.com.tw\/daily-biohealth\/2026-07-17\/"},"modified":"2026-07-17T10:47:57","modified_gmt":"2026-07-17T02:47:57","slug":"9-96","status":"publish","type":"page","link":"https:\/\/witology.com.tw\/en\/daily-biohealth\/9-96\/","title":{"rendered":"\u751f\u91ab\u5927\u5065\u5eb7\u7522\u696d\u65e5\u5831 2026-07-17\uff5cEli Lilly \u65a5\u8cc7\u91cd\u91d1\u6536\u8cfc\u8ff7\u5e7b\u85e5\u5ee0 AtaiB"},"content":{"rendered":"\n<style>.wit-daily {\n  --bg:#0f0e0c;--bg2:#16140f;--fg:#e8e3d8;--dim:#8a8276;--mute:#5a5448;\n  --card:#1a1816;--card2:#221f1b;--bdr:#3a342e;--bdr2:#4a423a;\n  --acc:#c4b09a;--acc2:#d4a574;--acc3:#7a6e62;\n  --tw:#e07a6a;--us:#7ab3d4;\n  --up:#8fc78a;--dn:#d97070;--nu:#9a9282;\n  --warn:#d4a574;\n  --line-h:1.85;\n}\n.wit-daily * {margin:0;padding:0;box-sizing:border-box}\n.wit-daily {background:var(--bg)}\n.wit-daily {font-family:\"Noto Sans TC\",sans-serif;background:var(--bg);color:var(--fg);line-height:var(--line-h);-webkit-font-smoothing:antialiased;background-image:radial-gradient(ellipse 80% 40% at 50% 0%,rgba(196,176,154,.06),transparent 70%)}\n.wit-daily .wrap {max-width:860px;margin:0 auto;padding:40px 22px 80px}\n.wit-daily .hdr {text-align:center;padding:64px 0 48px;margin-bottom:48px;border-bottom:1px solid var(--bdr)}\n.wit-daily .hdr-date {font-size:12px;letter-spacing:8px;color:var(--acc);text-transform:uppercase;margin-bottom:14px;font-weight:500}\n.wit-daily .hdr h1 {font-family:\"Noto Serif TC\",serif;font-size:clamp(30px,5vw,46px);font-weight:700;letter-spacing:3px;margin-bottom:12px;background:linear-gradient(135deg,var(--fg) 0%,var(--acc) 100%);-webkit-background-clip:text;-webkit-text-fill-color:transparent;background-clip:text}\n.wit-daily .hdr-sub {font-size:13px;color:var(--dim);letter-spacing:1px}\n.wit-daily .stats {margin-bottom:48px}\n.wit-daily .st {display:flex;align-items:center;gap:12px;margin-bottom:8px}\n.wit-daily .st-bar {height:3px;border-radius:2px;min-width:3px;transition:width .5s;opacity:.85}\n.wit-daily .st-lb {font-size:13px;flex:1;color:var(--fg)}\n.wit-daily .st-ct {font-size:12px;color:var(--dim);min-width:24px;text-align:right;font-variant-numeric:tabular-nums}\n.wit-daily .lbl {font-family:\"Noto Serif TC\",serif;font-size:24px;font-weight:700;color:var(--fg);margin-bottom:28px;padding-bottom:12px;border-bottom:2px solid var(--acc);letter-spacing:1px}\n.wit-daily .c {background:var(--card);border:1px solid var(--bdr);border-radius:4px;margin-bottom:36px;overflow:hidden;box-shadow:0 4px 24px rgba(0,0,0,.35),0 1px 0 rgba(196,176,154,.05) inset;backdrop-filter:blur(16px)}\n.wit-daily .c-hd {display:flex;justify-content:space-between;align-items:center;padding:22px 30px 0}\n.wit-daily .c-cat {font-size:10px;font-weight:700;letter-spacing:3px;text-transform:uppercase;color:var(--cc,var(--acc));border:1px solid var(--cc,var(--acc));padding:3px 12px;border-radius:2px;background:rgba(0,0,0,.2)}\n.wit-daily .c-snt {font-size:13px;font-weight:600;letter-spacing:.5px}\n.wit-daily .s-up {color:var(--up)}\n.wit-daily .s-dn {color:var(--dn)}\n.wit-daily .s-nu {color:var(--nu)}\n.wit-daily .c-t {padding:14px 30px 4px;font-family:\"Noto Serif TC\",serif;font-size:24px;font-weight:700;line-height:1.45;letter-spacing:.5px}\n.wit-daily .c-t a {color:var(--fg);text-decoration:none;transition:color .25s}\n.wit-daily .c-t a:hover {color:var(--acc2)}\n.wit-daily .c-src {padding:0 30px 14px;font-size:12px;color:var(--dim);letter-spacing:.5px}\n.wit-daily .c-hype {display:flex;align-items:center;gap:14px;padding:10px 30px 14px;border-top:1px dashed var(--bdr);border-bottom:1px dashed var(--bdr);background:rgba(196,176,154,.03)}\n.wit-daily .c-hype-lb {font-size:10px;letter-spacing:2px;text-transform:uppercase;color:var(--dim);font-weight:700}\n.wit-daily .c-hype-dots {font-size:14px;color:var(--acc2);letter-spacing:3px;font-family:monospace}\n.wit-daily .c-hype-tx {font-size:12px;color:var(--acc);font-weight:500}\n.wit-daily .c-stocks {padding:14px 30px 18px;display:flex;flex-wrap:wrap;gap:6px}\n.wit-daily .stk {display:inline-flex;align-items:center;gap:4px;font-size:12px;padding:4px 12px;border-radius:2px;font-weight:500}\n.wit-daily .stk b {font-weight:700}\n.wit-daily .stk-tw {background:rgba(224,122,106,.12);color:var(--tw);border:1px solid rgba(224,122,106,.35)}\n.wit-daily .stk-us {background:rgba(122,179,212,.12);color:var(--us);border:1px solid rgba(122,179,212,.35)}\n.wit-daily .stk-other {background:rgba(255,255,255,.04);color:var(--dim);border:1px solid var(--bdr2)}\n.wit-daily .chg {font-size:11px;font-weight:600;padding:1px 6px;border-radius:2px;margin-left:2px}\n.wit-daily .chg-up {background:rgba(226,100,80,.20);color:#ff8f78}\n.wit-daily .chg-down {background:rgba(94,181,141,.20);color:#7ed0a6}\n.wit-daily .chg-flat {background:rgba(255,255,255,.06);color:var(--dim)}\n.wit-daily .c-img {width:100%;height:auto;aspect-ratio:1170\/540;object-fit:cover;border-top:1px solid var(--bdr);border-bottom:1px solid var(--bdr);filter:brightness(.92);display:block}\n.wit-daily .c-analysis {display:grid;grid-template-columns:1fr 1fr;border-top:1px solid var(--bdr)}\n.wit-daily .c-sec {padding:22px 30px;border-bottom:1px solid var(--bdr)}\n.wit-daily .c-sec:nth-child(odd) {border-right:1px solid var(--bdr)}\n.wit-daily .c-wide {grid-column:1\/-1;border-right:none !important}\n.wit-daily .c-sec h4 {font-size:14px;letter-spacing:2px;text-transform:uppercase;color:var(--acc);margin-bottom:12px;font-weight:700}\n.wit-daily .c-sec p {font-size:14px;line-height:var(--line-h);color:var(--fg);opacity:.92}\n.wit-daily .c-counter {background:rgba(212,165,116,.05)}\n.wit-daily .c-counter h4 {color:var(--warn)}\n.wit-daily .c-counter blockquote {border-left:3px solid var(--warn);padding:6px 0 6px 16px;font-size:14px;line-height:var(--line-h);color:var(--fg);opacity:.92;font-style:italic;margin:0}\n.wit-daily .c-watch {background:rgba(196,176,154,.04)}\n.wit-daily .c-watch-grid {display:grid;grid-template-columns:1fr 1fr 1fr;gap:18px;margin-top:6px}\n.wit-daily .c-watch-col {}\n.wit-daily .c-watch-h {font-size:12px;font-weight:700;color:var(--fg);margin-bottom:10px;padding-bottom:6px;border-bottom:1px solid var(--bdr2);display:flex;flex-direction:column;gap:2px}\n.wit-daily .c-watch-h span {font-size:10px;color:var(--dim);letter-spacing:1px;font-weight:400}\n.wit-daily .c-w-short {border-bottom-color:var(--dn)}\n.wit-daily .c-w-mid {border-bottom-color:var(--acc2)}\n.wit-daily .c-w-long {border-bottom-color:var(--up)}\n.wit-daily .c-watch-col ul {list-style:none;padding:0;margin:0}\n.wit-daily .c-watch-col li {font-size:13px;line-height:1.7;color:var(--fg);opacity:.88;padding:6px 0 6px 16px;position:relative}\n.wit-daily .c-watch-col li:before {content:\"\u25b8\";position:absolute;left:0;color:var(--acc);font-size:12px}\n.wit-daily .c-faqs {background:rgba(122,179,212,.04)}\n.wit-daily .c-faqs h4 {color:var(--us)}\n.wit-daily .c-faq-item {border-bottom:1px solid var(--bdr);padding:10px 0}\n.wit-daily .c-faq-item:last-child {border-bottom:none}\n.wit-daily .c-faq-item summary {cursor:pointer;font-size:14px;font-weight:600;color:var(--fg);padding:6px 0;list-style:none;display:flex;align-items:center;gap:10px;transition:color .2s}\n.wit-daily .c-faq-item summary::before {content:\"+\";color:var(--us);font-weight:700;font-size:18px;width:14px;display:inline-block;transition:transform .2s}\n.wit-daily .c-faq-item[open] summary::before {content:\"\u2212\"}\n.wit-daily .c-faq-item summary:hover {color:var(--acc2)}\n.wit-daily .c-faq-item p {font-size:13px;line-height:1.8;color:var(--fg);opacity:.85;padding:8px 0 6px 24px;margin:0}\n.wit-daily .c-ft {padding:16px 30px;border-top:1px solid var(--bdr);text-align:right;background:rgba(0,0,0,.15)}\n.wit-daily .c-ft a {font-size:13px;color:var(--acc);text-decoration:none;font-weight:500;transition:color .25s;letter-spacing:.5px}\n.wit-daily .c-ft a:hover {color:var(--acc2)}\n.wit-daily .briefs {background:var(--card);border:1px solid var(--bdr);border-radius:4px;padding:8px 0;margin-bottom:48px;box-shadow:0 2px 12px rgba(0,0,0,.25)}\n.wit-daily .b-item {display:flex;gap:12px;padding:12px 26px;border-bottom:1px solid var(--bdr);align-items:flex-start}\n.wit-daily .b-item:last-child {border-bottom:none}\n.wit-daily .b-dot {width:7px;height:7px;border-radius:50%;margin-top:9px;flex-shrink:0;box-shadow:0 0 8px currentColor}\n.wit-daily .b-link {color:var(--fg);text-decoration:none;font-size:14px;transition:color .25s;display:block;margin-bottom:2px;line-height:1.6}\n.wit-daily .b-link:hover {color:var(--acc2)}\n.wit-daily .b-meta {font-size:11px;color:var(--dim);letter-spacing:.5px}\n.wit-daily .ftr {text-align:center;padding:36px 0;font-size:11px;color:var(--mute);border-top:1px solid var(--bdr);margin-top:24px;letter-spacing:1px}\n@media(max-width:680px) {.wit-daily .c-analysis {grid-template-columns:1fr}\n.wit-daily .c-sec:nth-child(odd) {border-right:none}\n.wit-daily .c-wide {grid-column:1}\n.wit-daily .c-t {font-size:19px;padding:12px 20px 4px}\n.wit-daily .c-hd, .wit-daily .c-src, .wit-daily .c-stocks, .wit-daily .c-sec, .wit-daily .c-ft, .wit-daily .c-hype {padding-left:20px;padding-right:20px}\n.wit-daily .c-watch-grid {grid-template-columns:1fr;gap:14px}}\n\/* \u5168\u57df(\u975e scoped):\u50c5\u8a72\u7522\u696d\u65e5\u5831\u5b50\u9801\u751f\u6548 *\/\nbody.parent-pageid-7356 .fusion-page-title-bar,\nbody.parent-pageid-7356 .fusion-page-title-row,\nbody.parent-pageid-7356 .fusion-page-title-wrapper {\n  display: none !important;\n  height: 0 !important;\n  padding: 0 !important;\n  margin: 0 !important;\n}\nbody.parent-pageid-7356 #main,\nbody.parent-pageid-7356 #content,\nbody.parent-pageid-7356 .fusion-row,\nbody.parent-pageid-7356 .post-content,\nbody.parent-pageid-7356 article.post {\n  padding-top: 0 !important;\n  margin-top: 0 !important;\n}\n\n\/* scoped(.wit-daily) *\/\n.wit-daily {\n  margin-left: calc((100% - 100vw) \/ 2);\n  margin-right: calc((100% - 100vw) \/ 2);\n  padding-left: calc((100vw - 100%) \/ 2);\n  padding-right: calc((100vw - 100%) \/ 2);\n  padding-top: 40px;\n  padding-bottom: 60px;\n  background: #0f0e0c;\n  color: #e8e3d8;\n  font-family: \"Noto Sans TC\", sans-serif;\n}\n.wit-daily .wrap { padding-left: 22px; padding-right: 22px; padding-top: 0; }\n.wit-daily a { color: inherit; }\n\/* \u5f37\u5236\u8986\u84cb Avada \u4e3b\u984c\u53ef\u80fd\u6ce8\u5165\u7684 blockquote \u767d\u5e95 *\/\n.wit-daily .c-counter blockquote,\n.wit-daily blockquote {\n  background: transparent !important;\n  background-color: transparent !important;\n  color: #e8e3d8 !important;\n  border-left: 3px solid #d4a574 !important;\n  padding: 6px 0 6px 16px !important;\n  font-style: italic !important;\n  margin: 0 !important;\n  box-shadow: none !important;\n}\n.wit-daily .c-counter blockquote::before,\n.wit-daily blockquote::before,\n.wit-daily blockquote::after { content: none !important; }\n<\/style>\n<div class=\"wit-daily\">\n\n<main class=\"wrap\">\n<header class=\"hdr\">\n<div class=\"hdr-date\"><time datetime=\"2026-07-17\">2026 \u5e74 07 \u6708 17 \u65e5<\/time><\/div>\n<h1>\u751f\u91ab\u5927\u5065\u5eb7\u7522\u696d\u65e5\u5831<\/h1>\n<p class=\"hdr-sub\">\u5171\u6536\u9304 5 \u5247\u7522\u696d\u76f8\u95dc\u65b0\u805e \u00b7 2 \u5247\u7cbe\u9078\u6df1\u5ea6\u5206\u6790<\/p>\n<\/header>\n<section aria-labelledby=\"sec-featured\">\n<h2 class=\"lbl\" id=\"sec-featured\">\u7cbe\u9078\u6df1\u5ea6\u5206\u6790<\/h2>\n<article class=\"c\" itemscope=\"\" itemtype=\"https:\/\/schema.org\/NewsArticle\">\n<header class=\"c-hd\">\n<span class=\"c-cat\" style=\"--cc:#4472C4\">\u85e5\u7269<\/span>\n<span class=\"c-snt s-up\">\u25b2 \u504f\u591a<\/span>\n<\/header>\n<h3 class=\"c-t\" itemprop=\"headline\"><a href=\"https:\/\/finance.technews.tw\/2026\/07\/17\/lilly-enters-psychedelic-drug-race-with-up-to-3-8-billion-ataibeckley-deal\/\" rel=\"noopener nofollow\" target=\"_blank\">Eli Lilly \u65a5\u8cc7\u91cd\u91d1\u6536\u8cfc\u8ff7\u5e7b\u85e5\u5ee0 AtaiBeckley\uff0c\u80a1\u50f9\u98c6\u6f32 33%<\/a><\/h3>\n<div class=\"c-src\">\u4f86\u6e90\uff1a<span itemprop=\"publisher\">\u79d1\u6280\u65b0\u5831<\/span> \u00b7 <time datetime=\"2026-07-17\" itemprop=\"datePublished\">2026-07-17T02:20:59<\/time><\/div>\n<div class=\"c-hype\"><span class=\"c-hype-lb\">\u7522\u696d\u91cd\u8981\u6027<\/span><span class=\"c-hype-dots\">\u25cf\u25cf\u25cf\u25cf\u25cb<\/span><span class=\"c-hype-tx\">4\/5 \u00b7 \u91cd\u5927\u8a0a\u865f<\/span><\/div>\n<div class=\"c-stocks\"><span class=\"stk stk-us\"><b>LLY<\/b> Eli Lilly <span class=\"chg chg-up\">\u25b21.08% $1169.17<\/span><\/span><span class=\"stk stk-us\"><b>ATAI<\/b> atai Life Sciences <span class=\"chg chg-up\">\u25b233.40% $7.15<\/span><\/span><span class=\"stk stk-other\">Beckley Psytech <span class=\"chg chg-flat\">\u672a\u4e0a\u5e02<\/span><\/span><span class=\"stk stk-us\"><b>CMPS<\/b> COMPASS Pathways <span class=\"chg chg-down\">\u25bc6.61% $12.43<\/span><\/span><span class=\"stk stk-us\"><b>MNMD<\/b> MindMed <span class=\"chg chg-flat\">\u2014<\/span><\/span><span class=\"stk stk-us\"><b>JNJ<\/b> Johnson &amp; Johnson <span class=\"chg chg-up\">\u25b21.19% $249.97<\/span><\/span><\/div>\n<img decoding=\"async\" alt=\"Eli Lilly \u65a5\u8cc7\u91cd\u91d1\u6536\u8cfc\u8ff7\u5e7b\u85e5\u5ee0 AtaiBeckley\uff0c\u80a1\u50f9\u98c6\u6f32 33%\" class=\"lazyload c-img\" height=\"540\" loading=\"lazy\" src=\"data:image\/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%271170%27%20height%3D%27540%27%20viewBox%3D%270%200%201170%20540%27%3E%3Crect%20width%3D%271170%27%20height%3D%27540%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E\" data-orig-src=\"https:\/\/witology.com.tw\/wp-content\/uploads\/2026\/07\/featured_1-36.png\" width=\"1170\"\/>\n<section class=\"c-analysis\" itemprop=\"articleBody\">\n<div class=\"c-sec\">\n<h4>\u95dc\u9375\u4e8b\u4ef6<\/h4>\n<p>Eli Lilly \u5ba3\u5e03\u4ee5\u6700\u9ad8\u7d04 38 \u5104\u7f8e\u5143\u6536\u8cfc\u8ff7\u5e7b\u85e5\u958b\u767c\u5546 AtaiBeckley\uff08atai Life Sciences \u8207 Beckley Psytech \u7684\u5408\u4f75\u5be6\u9ad4\uff09\uff0c\u6b63\u5f0f\u8de8\u5165\u7cbe\u795e\u79d1\u8ff7\u5e7b\u7642\u6cd5\u8cfd\u9053\u3002\u6b64\u8209\u4ee3\u8868\u5168\u7403\u5e02\u503c\u6700\u9ad8\u85e5\u5ee0\u4e4b\u4e00\u9996\u5ea6\u5927\u898f\u6a21\u62bc\u6ce8\u88f8\u84cb\u83c7\u7d20\uff08psilocybin\uff09\u3001DMT \u7b49\u8ff7\u5e7b\u7269\u8cea\u4f5c\u70ba\u7cbe\u795e\u75be\u75c5\u6cbb\u7642\u85e5\u7269\uff0cAtaiBeckley \u80a1\u50f9\u55ae\u65e5\u66b4\u6f32\u903e 33%\u3002\u9019\u662f\u7e7c J&amp;J ketamine \u884d\u751f\u7269 Spravato \u4e4b\u5f8c\uff0c\u4e3b\u6d41\u5927\u85e5\u5ee0\u5c0d\u610f\u8b58\u6539\u8b8a\u7642\u6cd5\u6700\u5927\u898f\u6a21\u7684\u8cc7\u672c\u6295\u5165\u3002<\/p>\n<\/div>\n<div class=\"c-sec\">\n<h4>\u95dc\u9375\u6578\u64da<\/h4>\n<p>\u6536\u8cfc\u91d1\u984d\u4e0a\u9650\u7d04 38 \u5104\u7f8e\u5143\uff1bAtaiBeckley \u80a1\u50f9\u55ae\u65e5\u98c6\u6f32 33%\uff1b\u5168\u7403\u6182\u9b31\u75c7\u5e02\u5834\u898f\u6a21\u9810\u8a08 2030 \u5e74\u8d85\u904e 180 \u5104\u7f8e\u5143\uff1b\u88f8\u84cb\u83c7\u7d20\u7642\u6cd5\u5728 FDA \u7a81\u7834\u6027\u7642\u6cd5\u8a8d\u5b9a\u4e0b\uff0cPhase 2 \u7de9\u89e3\u7387\u90e8\u5206\u8a66\u9a57\u9054 40\u201350%\uff0c\u9060\u9ad8\u65bc\u50b3\u7d71 SSRI \u7684 30\u201335%\uff1bJ&amp;J Spravato 2023 \u5e74\u92b7\u552e\u984d\u7d04 8 \u5104\u7f8e\u5143\uff0c\u70ba\u8ff7\u5e7b\/\u89e3\u96e2\u985e\u85e5\u7269\u5546\u696d\u5316\u63d0\u4f9b\u53c3\u8003\u57fa\u6e96\u3002<\/p>\n<\/div>\n<div class=\"c-sec c-wide\">\n<h4>\u5e02\u5834\u91cd\u8981\u6027<\/h4>\n<p>Eli Lilly \u4ee5\u8fd1 38 \u5104\u7f8e\u5143\u9032\u5834\uff0c\u6a19\u8a8c\u8457\u8ff7\u5e7b\u7642\u6cd5\u5f9e\u5c0f\u773e\u65b0\u5275\u6b63\u5f0f\u9032\u5165\u4e3b\u6d41\u88fd\u85e5\u7248\u5716\uff0c\u5c07\u52a0\u901f\u6574\u500b\u8cfd\u9053\u7684\u76e3\u7ba1\u8a0e\u8ad6\u8207\u8cc7\u672c\u6d41\u5165\u3002Lilly \u672c\u8eab\u56e0 GLP-1 \u85e5\u7269\u5750\u64c1\u9f90\u5927\u73fe\u91d1\u6d41\uff0c\u9078\u64c7\u5728\u7cbe\u795e\u79d1\u9818\u57df\u4f48\u5c40\uff0c\u986f\u793a\u5927\u85e5\u5ee0\u5df2\u5c07\u5fc3\u7406\u5065\u5eb7\u8996\u70ba\u4e0b\u4e00\u500b\u9ad8\u503c\u5e02\u5834\uff1b\u76f8\u6bd4\u4e4b\u4e0b\uff0c\u73fe\u6709 SSRI\/SNRI \u5e02\u5834\u9762\u81e8\u5c08\u5229\u61f8\u5d16\u4e14\u7642\u6548\u5929\u82b1\u677f\u660e\u986f\uff0c\u7d50\u69cb\u6027\u66ff\u4ee3\u9700\u6c42\u5f37\u70c8\u3002\u5c0d\u53f0\u7063\u7522\u696d\u800c\u8a00\uff0c\u8ff7\u5e7b\u7269\u8cea\u5c6c\u65bc\u9ad8\u5ea6\u7ba1\u5236\u539f\u6599\u85e5\uff0c\u672c\u571f CDMO \u82e5\u5177\u5099\u7b2c\u4e8c\u985e\u7ba1\u5236\u85e5\u54c1\u5408\u6210\u80fd\u529b\uff08\u5982\u53f0\u7063\u795e\u9686\uff09\uff0c\u5177\u5099\u6f5b\u5728\u4ee3\u5de5\u5207\u5165\u6a5f\u6703\uff1b\u4f46\u77ed\u671f\u5167\u76e3\u7ba1\u6846\u67b6\u5c1a\u672a\u5efa\u7acb\uff0c\u5546\u696d\u5316\u6642\u7a0b\u4ecd\u5b58\u4e0d\u78ba\u5b9a\u6027\u3002<\/p>\n<\/div>\n<div class=\"c-sec c-wide c-counter\">\n<h4>\u26a0 \u53cd\u9762\u89c0\u9ede<\/h4>\n<blockquote>\u8ff7\u5e7b\u7642\u6cd5\u7684\u81e8\u5e8a\u8a66\u9a57\u666e\u904d\u9762\u81e8\u300c\u76f2\u5316\u56f0\u96e3\u300d\u554f\u984c\u2014\u2014\u53d7\u8a66\u8005\u5e7e\u4e4e\u90fd\u80fd\u611f\u77e5\u81ea\u5df1\u662f\u5426\u670d\u7528\u4e86\u6d3b\u6027\u85e5\u7269\uff0c\u5c0e\u81f4\u5b89\u6170\u5291\u5c0d\u7167\u8a2d\u8a08\u5929\u7136\u5b58\u5728\u504f\u5dee\uff0cPhase 3 \u6578\u64da\u6709\u9ad8\u5ea6\u88ab\u63a8\u7ffb\u7684\u98a8\u96aa\uff1b\u6b64\u5916 FDA \u5c0d\u88f8\u84cb\u83c7\u7d20\u7684\u76e3\u7ba1\u8def\u5f91\u5c1a\u672a\u660e\u78ba\uff0c38 \u5104\u7f8e\u5143\u7684\u6536\u8cfc\u50f9\u82e5\u6700\u7d42\u7121\u6cd5\u53d6\u5f97\u85e5\u8b49\uff0c\u5c07\u6210\u70ba Lilly \u7e7c GLP-1 \u8f1d\u714c\u5f8c\u7684\u4e00\u6b21\u4ee3\u50f9\u9ad8\u6602\u7684\u591a\u5143\u5316\u8ced\u6ce8\u3002<\/blockquote>\n<\/div>\n<div class=\"c-sec c-wide c-watch\">\n<h4>\ud83d\udccd \u63a5\u4e0b\u4f86\u89c0\u5bdf<\/h4>\n<div class=\"c-watch-grid\">\n<div class=\"c-watch-col\"><div class=\"c-watch-h c-w-short\">\ud83d\udd25 \u77ed\u671f\u50ac\u5316\u5291<span>1-3 \u500b\u6708<\/span><\/div><ul><li>AtaiBeckley \u65d7\u4e0b\u4e3b\u8981\u7ba1\u7dda\uff08\u88f8\u84cb\u83c7\u7d20\u3001\u77ed\u6548 DMT\uff09\u7684\u6700\u65b0 Phase 2\/3 \u8a66\u9a57\u6578\u64da\u8b80\u51fa\u6642\u7a0b\u78ba\u8a8d<\/li><li>FDA \u5c0d\u88f8\u84cb\u83c7\u7d20\u65b0\u85e5\u7533\u8acb\u8def\u5f91\u7684\u6b63\u5f0f\u8868\u614b\u6216\u6307\u5c0e\u6587\u4ef6\u662f\u5426\u66f4\u65b0<\/li><\/ul><\/div>\n<div class=\"c-watch-col\"><div class=\"c-watch-h c-w-mid\">\ud83d\udc41 \u4e2d\u671f\u89c0\u5bdf<span>3-12 \u500b\u6708<\/span><\/div><ul><li>COMPASS Pathways\u3001MindMed \u7b49\u540c\u8cfd\u9053\u7af6\u722d\u8005\u662f\u5426\u8ddf\u9032\u88ab\u5927\u85e5\u5ee0\u6536\u8cfc\u6216\u5c0b\u6c42\u6388\u6b0a\u5408\u4f5c<\/li><li>Eli Lilly \u6574\u5408 AtaiBeckley \u5f8c\u7684\u7ba1\u7dda\u512a\u5148\u9806\u5e8f\u53ca\u8ffd\u52a0\u7814\u767c\u9810\u7b97\u898f\u6a21<\/li><\/ul><\/div>\n<div class=\"c-watch-col\"><div class=\"c-watch-h c-w-long\">\ud83c\udfaf \u9577\u671f\u8b8a\u6578<span>1 \u5e74\u4ee5\u4e0a<\/span><\/div><ul><li>\u8ff7\u5e7b\u7642\u6cd5\u662f\u5426\u80fd\u5efa\u7acb\u6a19\u6e96\u5316\u300c\u8f14\u52a9\u5fc3\u7406\u6cbb\u7642\u300d\u7d66\u4ed8\u6a21\u5f0f\uff0c\u7a81\u7834\u91ab\u7642\u4fdd\u96aa\u7d66\u4ed8\u58c1\u58d8<\/li><li>\u88f8\u84cb\u83c7\u7d20\u5408\u6210\u88fd\u9020\u7684 CMC\uff08\u5316\u5b78\u3001\u88fd\u9020\u8207\u7ba1\u5236\uff09\u6a19\u6e96\u5316\u9032\u7a0b\uff0c\u6c7a\u5b9a\u5168\u7403 CDMO \u4f9b\u61c9\u93c8\u683c\u5c40<\/li><\/ul><\/div>\n<\/div>\n<\/div>\n<div class=\"c-sec c-wide c-faqs\">\n<h4>\u2753 \u5e38\u898b\u554f\u984c<\/h4>\n<details class=\"c-faq-item\"><summary>Eli Lilly \u70ba\u4ec0\u9ebc\u8981\u82b1\u8fd1 38 \u5104\u7f8e\u5143\u8cb7\u4e00\u5bb6\u8ff7\u5e7b\u85e5\u516c\u53f8\uff1f<\/summary><p>Lilly \u76ee\u524d\u56e0 GLP-1 \u85e5\u7269\u7372\u5229\u8c50\u539a\uff0c\u6b63\u7a4d\u6975\u5c0b\u627e\u4e0b\u4e00\u500b\u9ad8\u6210\u9577\u9818\u57df\uff1b\u7cbe\u795e\u79d1\u5e02\u5834\u5c24\u5176\u6182\u9b31\u75c7\u3001PTSD \u7684\u672a\u6eff\u8db3\u9700\u6c42\u9f90\u5927\uff0c\u800c\u50b3\u7d71\u85e5\u7269\u7642\u6548\u6709\u9650\uff0c\u8ff7\u5e7b\u7642\u6cd5\u7684 Phase 2 \u7de9\u89e3\u7387\u6578\u64da\u9060\u512a\u65bc\u73fe\u6709\u6a19\u6e96\u7642\u6cd5\uff0c\u4f7f\u5176\u6210\u70ba\u5177\u9ad8\u5546\u696d\u6f5b\u529b\u7684\u5dee\u7570\u5316\u8ced\u6ce8\u3002<\/p><\/details><details class=\"c-faq-item\"><summary>\u8ff7\u5e7b\u85e5\u7642\u6cd5\u771f\u7684\u5408\u6cd5\u55ce\uff1fFDA \u6703\u6279\u51c6\u55ce\uff1f<\/summary><p>FDA \u5df2\u7d66\u4e88\u88f8\u84cb\u83c7\u7d20\u300c\u7a81\u7834\u6027\u7642\u6cd5\u300d\u8a8d\u5b9a\uff0c\u4f46\u5c1a\u672a\u6279\u51c6\u4efb\u4f55\u88f8\u84cb\u83c7\u7d20\u65b0\u85e5\uff1b\u76ee\u524d\u6700\u5927\u7684\u6311\u6230\u662f Phase 3 \u76f2\u5316\u8a2d\u8a08\u7684\u79d1\u5b78\u56b4\u8b39\u6027\uff0c\u4ee5\u53ca\u5982\u4f55\u5728\u91ab\u7642\u5834\u57df\u898f\u7bc4\u300c\u8f14\u52a9\u5fc3\u7406\u6cbb\u7642\u300d\u6d41\u7a0b\uff0c\u76e3\u7ba1\u8def\u5f91\u4ecd\u5728\u6478\u7d22\u4e2d\u3002<\/p><\/details><details class=\"c-faq-item\"><summary>AtaiBeckley \u80a1\u50f9\u6f32\u4e86 33%\uff0c\u5176\u4ed6\u8ff7\u5e7b\u85e5\u516c\u53f8\u4e5f\u6703\u8ddf\u8457\u53d7\u60e0\u55ce\uff1f<\/summary><p>\u77ed\u671f\u5167 COMPASS Pathways\u3001MindMed \u7b49\u540c\u8cfd\u9053\u516c\u53f8\u53ef\u671b\u53d7\u5230\u300c\u88ab\u6536\u8cfc\u9810\u671f\u300d\u5e36\u52d5\u4f30\u503c\u91cd\u65b0\u5b9a\u50f9\uff1b\u4f46\u82e5 Lilly \u7684\u4ea4\u6613\u662f\u6574\u500b\u5927\u85e5\u5ee0\u4f48\u5c40\u8ff7\u5e7b\u7642\u6cd5\u7684\u8d77\u9ede\uff0c\u5f8c\u7e8c\u7af6\u8cfc\u6f6e\u624d\u662f\u6301\u7e8c\u5229\u591a\uff0c\u5426\u5247\u677f\u584a\u6548\u61c9\u5c07\u5feb\u901f\u6d88\u9000\u3002<\/p><\/details>\n<\/div>\n<\/section>\n<footer class=\"c-ft\"><a href=\"https:\/\/finance.technews.tw\/2026\/07\/17\/lilly-enters-psychedelic-drug-race-with-up-to-3-8-billion-ataibeckley-deal\/\" rel=\"noopener nofollow\" target=\"_blank\">\u95b1\u8b80\u539f\u6587 \u2192<\/a><\/footer>\n<\/article>\n<article class=\"c\" itemscope=\"\" itemtype=\"https:\/\/schema.org\/NewsArticle\">\n<header class=\"c-hd\">\n<span class=\"c-cat\" style=\"--cc:#4472C4\">\u85e5\u7269<\/span>\n<span class=\"c-snt s-nu\">\u25ac \u4e2d\u6027<\/span>\n<\/header>\n<h3 class=\"c-t\" itemprop=\"headline\"><a href=\"https:\/\/www.fiercebiotech.com\/biotech\/vogenx-joins-ipo-queue-fund-phase-2-stage-metabolic-drug\" rel=\"noopener nofollow\" target=\"_blank\">Vogenx \u52a0\u5165 IPO \u6392\u968a\u884c\u5217\uff0c\u52df\u8cc7\u63a8\u9032 Phase 2 \u968e\u6bb5\u4ee3\u8b1d\u75be\u75c5\u85e5\u7269<\/a><\/h3>\n<div class=\"c-src\">\u4f86\u6e90\uff1a<span itemprop=\"publisher\">FierceBiotech<\/span> \u00b7 <time datetime=\"2026-07-17\" itemprop=\"datePublished\">2026-07-17<\/time><\/div>\n<div class=\"c-hype\"><span class=\"c-hype-lb\">\u7522\u696d\u91cd\u8981\u6027<\/span><span class=\"c-hype-dots\">\u25cf\u25cf\u25cb\u25cb\u25cb<\/span><span class=\"c-hype-tx\">2\/5 \u00b7 \u6b21\u8981\u52d5\u614b<\/span><\/div>\n<div class=\"c-stocks\"><span class=\"stk stk-other\">Vogenx <span class=\"chg chg-flat\">\u672a\u4e0a\u5e02<\/span><\/span><span class=\"stk stk-us\"><b>LLY<\/b> Eli Lilly <span class=\"chg chg-up\">\u25b21.08% $1169.17<\/span><\/span><span class=\"stk stk-us\"><b>NVO<\/b> Novo Nordisk <span class=\"chg chg-up\">\u25b21.82% $51.48<\/span><\/span><span class=\"stk stk-us\"><b>GPCR<\/b> Structure Therapeutics <span class=\"chg chg-down\">\u25bc7.23% $46.03<\/span><\/span><span class=\"stk stk-us\"><b>ALT<\/b> Altimmune <span class=\"chg chg-down\">\u25bc4.36% $2.85<\/span><\/span><span class=\"stk stk-us\"><b>VKTX<\/b> Viking Therapeutics <span class=\"chg chg-down\">\u25bc3.81% $36.37<\/span><\/span><span class=\"stk stk-tw\"><b>4162<\/b> \u667a\u64ce\u751f\u6280 <span class=\"chg chg-flat\">\u2014<\/span><\/span><\/div>\n<section class=\"c-analysis\" itemprop=\"articleBody\">\n<div class=\"c-sec\">\n<h4>\u95dc\u9375\u4e8b\u4ef6<\/h4>\n<p>\u4ee3\u8b1d\u75be\u75c5\u65b0\u5275 Vogenx \u5ba3\u5e03\u555f\u52d5 IPO \u7a0b\u5e8f\uff0c\u8a08\u756b\u900f\u904e\u4e0a\u5e02\u52df\u96c6\u8cc7\u91d1\u63a8\u9032\u5176\u6838\u5fc3\u4ee3\u8b1d\u85e5\u7269\u9032\u5165 Phase 2 \u81e8\u5e8a\u8a66\u9a57\u3002\u6b64\u8209\u53cd\u6620\u7576\u524d\u751f\u6280 IPO \u5e02\u5834\u5728 GLP-1 \u71b1\u6f6e\u5e36\u52d5\u4e0b\uff0c\u4ee3\u8b1d\u75be\u75c5\u7ba1\u7dda\u4f9d\u7136\u662f\u8cc7\u672c\u5e02\u5834\u7684\u5438\u91d1\u78c1\u9435\uff1b\u7136\u800c Vogenx \u5c1a\u8655 Phase 2 \u524d\u671f\uff0c\u8ddd\u96e2\u5546\u696d\u5316\u4ecd\u6709\u76f8\u7576\u8ddd\u96e2\uff0cIPO \u6210\u529f\u8207\u5426\u9ad8\u5ea6\u53d6\u6c7a\u65bc\u5176\u5dee\u7570\u5316\u6a5f\u5236\u662f\u5426\u8db3\u4ee5\u5728 GLP-1 \u5de8\u982d\u74b0\u4f3a\u4e0b\u7372\u5f97\u6295\u8cc7\u4eba\u8a8d\u53ef\u3002<\/p>\n<\/div>\n<div class=\"c-sec\">\n<h4>\u95dc\u9375\u6578\u64da<\/h4>\n<p>\u5168\u7403\u4ee3\u8b1d\u75be\u75c5\uff08\u542b\u7cd6\u5c3f\u75c5\u3001\u80a5\u80d6\u3001\u975e\u9152\u7cbe\u6027\u8102\u80aa\u809d NASH\uff09\u85e5\u7269\u5e02\u5834 2030 \u5e74\u9810\u4f30\u8d85\u904e 1,000 \u5104\u7f8e\u5143\uff1bGLP-1 \u9f8d\u982d Lilly Zepbound \u8207 Novo Nordisk Wegovy \u5408\u8a08 2024 \u5e74\u71df\u6536\u8d85\u904e 150 \u5104\u7f8e\u5143\uff1b2024\u20132025 \u5e74\u751f\u6280 IPO \u5e02\u5834\u4e2d\uff0c\u4ee3\u8b1d\/\u80a5\u80d6\u76f8\u95dc\u7ba1\u7dda\u4f30\u503c\u6ea2\u50f9\u5e73\u5747\u9054 30\u201350%\uff1bPhase 2 \u4ee3\u8b1d\u85e5\u7269 IPO \u5e73\u5747\u52df\u8cc7\u898f\u6a21\u7d04 1\u20132 \u5104\u7f8e\u5143\u3002<\/p>\n<\/div>\n<div class=\"c-sec c-wide\">\n<h4>\u5e02\u5834\u91cd\u8981\u6027<\/h4>\n<p>Vogenx \u7684 IPO \u7533\u8acb\u662f GLP-1 \u71b1\u6f6e\u5916\u6ea2\u81f3\u8cc7\u672c\u5e02\u5834\u7684\u5177\u9ad4\u9ad4\u73fe\uff0c\u4ee3\u8b1d\u75be\u75c5\u8cfd\u9053\u4ecd\u662f 2025\u20132026 \u5e74\u751f\u6280 IPO \u6700\u5177\u5438\u5f15\u529b\u7684\u4e3b\u984c\u4e4b\u4e00\u3002\u7136\u800c\u96a8\u8457 Lilly\u3001Novo Nordisk \u7684\u4e0b\u4e00\u4ee3\u53e3\u670d GLP-1 \u7ba1\u7dda\u9010\u6f38\u6210\u719f\uff0c\u5c0f\u578b\u65b0\u5275\u82e5\u7121\u660e\u78ba\u7684\u5dee\u7570\u5316\u6a5f\u5236\uff08\u5982\u975e GLP-1 \u8def\u5f91\u3001NASH \u9069\u61c9\u75c7\u3001\u53e3\u670d\u5291\u578b\u512a\u52e2\uff09\uff0c\u5728 Phase 2 \u6578\u64da\u51fa\u7210\u524d\u5c07\u9762\u81e8\u6975\u9ad8\u7684\u4f30\u503c\u58d3\u529b\u3002\u5c0d\u53f0\u7063\u6295\u8cc7\u4eba\u800c\u8a00\uff0c\u6b64\u985e Phase 2 \u524d\u671f IPO \u6848\u4f8b\u53ef\u4f5c\u70ba\u89c0\u5bdf\u570b\u969b\u4ee3\u8b1d\u75be\u75c5\u85e5\u7269\u7814\u767c\u8da8\u52e2\u8207\u878d\u8cc7\u74b0\u5883\u7684\u98a8\u5411\u6a19\uff0c\u4f46\u76f4\u63a5\u6295\u8cc7\u98a8\u96aa\u986f\u8457\u9ad8\u65bc\u5df2\u6709 Phase 3 \u6578\u64da\u7684\u516c\u53f8\u3002<\/p>\n<\/div>\n<div class=\"c-sec c-wide c-counter\">\n<h4>\u26a0 \u53cd\u9762\u89c0\u9ede<\/h4>\n<blockquote>\u4ee3\u8b1d\u75be\u75c5 IPO \u5e02\u5834\u5df2\u51fa\u73fe\u904e\u71b1\u8de1\u8c61\u2014\u20142023\u20132024 \u5e74\u6578\u5341\u5bb6\u80a5\u80d6\/NASH \u65b0\u5275\u7d1b\u7d1b\u4e0a\u5e02\uff0c\u4f46\u591a\u6578\u5728 GLP-1 \u5de8\u982d\u5f37\u5927\u7684\u8cc7\u6599\u58c1\u58d8\u8207\u54c1\u724c\u6548\u61c9\u4e0b\uff0cPhase 2 \u6578\u64da\u5373\u4fbf\u967d\u6027\u4e5f\u96e3\u4ee5\u53d6\u5f97\u6388\u6b0a\u5408\u4f5c\uff0cVogenx \u5728\u6a5f\u5236\u672a\u5145\u5206\u63ed\u9732\u524d\uff0cIPO \u66f4\u50cf\u662f\u98a8\u96aa\u8f49\u79fb\u7d66\u6563\u6236\u7684\u8ca1\u52d9\u64cd\u4f5c\uff0c\u800c\u975e\u771f\u6b63\u7684\u6280\u8853\u91cc\u7a0b\u7891\u3002<\/blockquote>\n<\/div>\n<div class=\"c-sec c-wide c-watch\">\n<h4>\ud83d\udccd \u63a5\u4e0b\u4f86\u89c0\u5bdf<\/h4>\n<div class=\"c-watch-grid\">\n<div class=\"c-watch-col\"><div class=\"c-watch-h c-w-short\">\ud83d\udd25 \u77ed\u671f\u50ac\u5316\u5291<span>1-3 \u500b\u6708<\/span><\/div><ul><li>Vogenx IPO \u62db\u80a1\u8aaa\u660e\u66f8\u516c\u958b\u5f8c\uff0c\u6838\u5fc3\u85e5\u7269\u4f5c\u7528\u6a5f\u5236\u8207\u9069\u61c9\u75c7\u7684\u5177\u9ad4\u63ed\u9732<\/li><li>IPO \u8a62\u50f9\u7d50\u679c\u8207\u6700\u7d42\u52df\u8cc7\u91d1\u984d\uff0c\u53cd\u6620\u5e02\u5834\u5c0d\u4ee3\u8b1d\u65b0\u5275\u7684\u771f\u5be6\u98a8\u96aa\u504f\u597d<\/li><\/ul><\/div>\n<div class=\"c-watch-col\"><div class=\"c-watch-h c-w-mid\">\ud83d\udc41 \u4e2d\u671f\u89c0\u5bdf<span>3-12 \u500b\u6708<\/span><\/div><ul><li>Phase 2 \u8a66\u9a57\u4e3b\u8981\u7642\u6548\u7d42\u9ede\uff08\u9ad4\u91cd\u964d\u4f4e%\u3001HbA1c \u7b49\uff09\u7684\u671f\u4e2d\u6578\u64da\u8b80\u51fa<\/li><li>\u662f\u5426\u5438\u5f15\u5927\u578b\u85e5\u5ee0\u9032\u884c\u6388\u6b0a\u8ac7\u5224\u6216\u7b56\u7565\u6295\u8cc7\uff0c\u4f5c\u70ba\u5546\u696d\u53ef\u884c\u6027\u9a57\u8b49<\/li><\/ul><\/div>\n<div class=\"c-watch-col\"><div class=\"c-watch-h c-w-long\">\ud83c\udfaf \u9577\u671f\u8b8a\u6578<span>1 \u5e74\u4ee5\u4e0a<\/span><\/div><ul><li>\u53e3\u670d\u5c0f\u5206\u5b50 GLP-1\/GIP \u6fc0\u52d5\u5291\uff08Lilly orforglipron\u3001Novo Nordisk \u53e3\u670d semaglutide\uff09\u4e0a\u5e02\u5f8c\u5c0d\u6ce8\u5c04\u578b\u53ca\u975e GLP-1 \u4ee3\u8b1d\u85e5\u7269\u5e02\u5834\u7684\u6392\u64e0\u6548\u61c9<\/li><li>NASH\/MASH\uff08\u4ee3\u8b1d\u76f8\u95dc\u8102\u80aa\u6027\u809d\u708e\uff09\u662f\u5426\u6210\u70ba\u4ee3\u8b1d\u85e5\u7269\u4e0b\u4e00\u500b\u4e3b\u6230\u5834\uff0c\u6c7a\u5b9a\u975e\u80a5\u80d6\u9069\u61c9\u75c7\u7684\u5e02\u5834\u7a7a\u9593<\/li><\/ul><\/div>\n<\/div>\n<\/div>\n<div class=\"c-sec c-wide c-faqs\">\n<h4>\u2753 \u5e38\u898b\u554f\u984c<\/h4>\n<details class=\"c-faq-item\"><summary>Vogenx \u7684\u4ee3\u8b1d\u85e5\u7269\u8ddf\u5e02\u9762\u4e0a\u7684 GLP-1 \u6e1b\u91cd\u85e5\u6709\u4ec0\u9ebc\u4e0d\u540c\uff1f<\/summary><p>\u76ee\u524d Vogenx \u7684\u5177\u9ad4\u4f5c\u7528\u6a5f\u5236\u5c1a\u672a\u5b8c\u6574\u516c\u958b\uff0c\u4f46\u4ee3\u8b1d\u75be\u75c5\u65b0\u5275\u901a\u5e38\u4ee5\u300c\u975e GLP-1 \u8def\u5f91\u300d\uff08\u5982 FGF21\u3001ACC \u6291\u5236\u5291\u3001mitochondria \u4ee3\u8b1d\u8abf\u7bc0\uff09\u6216\u300c\u53e3\u670d\u5291\u578b\u512a\u52e2\u300d\u4f5c\u70ba\u5dee\u7570\u5316\u8ce3\u9ede\uff0c\u8207 Lilly\/Novo Nordisk \u7684\u6ce8\u5c04\u578b GLP-1 \u5f62\u6210\u4e92\u88dc\u800c\u975e\u6b63\u9762\u7af6\u722d\u3002<\/p><\/details><details class=\"c-faq-item\"><summary>\u73fe\u5728\u9019\u500b\u6642\u9593\u9ede IPO \u5c0d Vogenx \u4f86\u8aaa\u662f\u597d\u6642\u6a5f\u55ce\uff1f<\/summary><p>\u4ee3\u8b1d\u75be\u75c5\u6982\u5ff5\u80a1\u4f30\u503c\u6ea2\u50f9\u5728 2024\u20132025 \u5e74\u4ecd\u76f8\u5c0d\u9ad8\u4f4d\uff0c\u8d95\u5728 Phase 2 \u6578\u64da\u51fa\u7210\u524d\u4e0a\u5e02\u53ef\u9396\u5b9a\u8f03\u9ad8\u4f30\u503c\uff1b\u4f46\u82e5 IPO \u5f8c\u6578\u64da\u4e0d\u5982\u9810\u671f\uff0c\u80a1\u50f9\u4fee\u6b63\u5e45\u5ea6\u901a\u5e38\u76f8\u7576\u5287\u70c8\uff0c\u6295\u8cc7\u4eba\u9700\u7559\u610f Phase 2 \u6578\u64da\u6642\u7a0b\u5e36\u4f86\u7684\u9ad8\u6ce2\u52d5\u98a8\u96aa\u3002<\/p><\/details><details class=\"c-faq-item\"><summary>\u9019\u5247\u65b0\u805e\u5c0d\u53f0\u7063\u4ee3\u8b1d\u75be\u75c5\u76f8\u95dc\u751f\u6280\u80a1\u6709\u5f71\u97ff\u55ce\uff1f<\/summary><p>\u77ed\u671f\u76f4\u63a5\u5f71\u97ff\u6709\u9650\uff0c\u4f46\u570b\u969b\u4ee3\u8b1d\u85e5\u7269\u8cfd\u9053\u6301\u7e8c\u71b1\u7d61\uff0c\u6709\u52a9\u65bc\u7dad\u6301\u5e02\u5834\u5c0d\u53f0\u7063\u4ee3\u8b1d\/\u7cd6\u5c3f\u75c5\u76f8\u95dc\u751f\u6280\u516c\u53f8\uff08\u5982\u7814\u767c NASH \u6216\u7cd6\u5c3f\u75c5\u85e5\u7269\u7684\u672c\u571f\u65b0\u5275\uff09\u7684\u95dc\u6ce8\u5ea6\u8207\u8a55\u50f9\u57fa\u6e96\u3002<\/p><\/details>\n<\/div>\n<\/section>\n<footer class=\"c-ft\"><a href=\"https:\/\/www.fiercebiotech.com\/biotech\/vogenx-joins-ipo-queue-fund-phase-2-stage-metabolic-drug\" rel=\"noopener nofollow\" target=\"_blank\">\u95b1\u8b80\u539f\u6587 \u2192<\/a><\/footer>\n<\/article>\n<\/section>\n<section aria-labelledby=\"sec-briefs\">\n<h2 class=\"lbl\" id=\"sec-briefs\">\u4eca\u65e5\u5feb\u8a0a<\/h2>\n<ul class=\"briefs\" style=\"list-style:none\">\n<li class=\"b-item\">\n<span class=\"b-dot\" style=\"background:#4472C4\"><\/span>\n<div><a class=\"b-link\" href=\"https:\/\/www.fiercebiotech.com\/biotech\/racing-takeda-innocare-reports-tyk2-inhibitor-win-phase-2-vitiligo-trial\" rel=\"noopener nofollow\" target=\"_blank\">Racing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trial<\/a>\n<span class=\"b-meta\">\u85e5\u7269 \u00b7 FierceBiotech<\/span><\/div>\n<\/li>\n<li class=\"b-item\">\n<span class=\"b-dot\" style=\"background:#70AD47\"><\/span>\n<div><a class=\"b-link\" href=\"https:\/\/www.fiercebiotech.com\/research\/axioms-wharton-jelly-stem-cell-therapy-posts-positive-phase-1-data-newborn-brain-injury\" rel=\"noopener nofollow\" target=\"_blank\">Why Axiom hopes it&#8217;s &#8216;solved 2 major potholes&#8217; that have hurt other stem cell biotechs<\/a>\n<span class=\"b-meta\">\u65b0\u8208\u7642\u6cd5 \u00b7 FierceBiotech<\/span><\/div>\n<\/li>\n<li class=\"b-item\">\n<span class=\"b-dot\" style=\"background:#FFC000\"><\/span>\n<div><a class=\"b-link\" href=\"https:\/\/www.fiercebiotech.com\/research\/nobel-laureate-jennifer-doudna-enters-ai-protein-design-arena\" rel=\"noopener nofollow\" target=\"_blank\">Nobel Laureate Jennifer Doudna enters AI protein design arena<\/a>\n<span class=\"b-meta\">\u751f\u547d\u79d1\u5b78 \u00b7 FierceBiotech<\/span><\/div>\n<\/li>\n<\/ul>\n<\/section>\n<section aria-labelledby=\"sec-stats\" class=\"stats\" style=\"margin-top:48px\">\n<h2 class=\"lbl\" id=\"sec-stats\" style=\"font-size:16px;border-bottom-width:1px\">\u5206\u985e\u7d71\u8a08<\/h2>\n<div class=\"st\"><div class=\"st-bar\" style=\"width:60.0%;background:#4472C4\"><\/div><span class=\"st-lb\">\u85e5\u7269<\/span><span class=\"st-ct\">3<\/span><\/div><div class=\"st\"><div class=\"st-bar\" style=\"width:20.0%;background:#70AD47\"><\/div><span class=\"st-lb\">\u65b0\u8208\u7642\u6cd5<\/span><span class=\"st-ct\">1<\/span><\/div><div class=\"st\"><div class=\"st-bar\" style=\"width:20.0%;background:#FFC000\"><\/div><span class=\"st-lb\">\u751f\u547d\u79d1\u5b78<\/span><span class=\"st-ct\">1<\/span><\/div>\n<\/section>\n<!-- footer \u5df2\u79fb\u9664(v2.14.0) -->\n<\/main>\n\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>2026 \u5e74 07 \u6708 17 \u65e5 \u751f\u91ab\u5927\u5065\u5eb7\u7522\u696d\u65e5\u5831 \u5171\u6536\u9304 5 \u5247\u7522\u696d\u76f8\u95dc\u65b0\u805e \u00b7 2 \u5247\u7cbe\u9078\u6df1\u5ea6\u5206\u6790 \u7cbe\u9078 [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"parent":7356,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":{"rank_math_title":"\u751f\u91ab\u5927\u5065\u5eb7\u7522\u696d\u65e5\u5831 2026-07-17\uff5cEli Lilly \u65a5\u8cc7\u91cd\u91d1\u6536\u8cfc\u8ff7\u5e7b\u85e5\u5ee0 AtaiB","rank_math_description":"2026 \u5e74 07 \u6708 17 \u65e5 \u751f\u91ab\u5927\u5065\u5eb7\u7522\u696d\u65e5\u5831\uff1aEli Lilly \u65a5\u8cc7\u91cd\u91d1\u6536\u8cfc\u8ff7\u5e7b\u85e5\u5ee0 AtaiBeckley\uff0c\u80a1\u50f9\u3001Vogenx \u52a0\u5165 IPO \u6392\u968a\u884c\u5217\uff0c\u52df\u8cc7\u63a8\u9032 Phase 2 \u968e\u6bb5\u4ee3\u3002\u5171\u6536\u9304 5 \u5247\u7522\u696d\u76f8\u95dc\u65b0\u805e,\u542b\u6df1\u5ea6\u5206\u6790\u3001\u53cd\u9762\u89c0\u9ede\u8207\u77ed\u4e2d\u9577\u671f\u89c0\u5bdf\u91cd\u9ede\u3002","rank_math_focus_keyword":"\u751f\u91ab\u5927\u5065\u5eb7","rank_math_robots":"","daily_schema_jsonld":"[\n  {\n    \"@context\": \"https:\/\/schema.org\",\n    \"@type\": \"CollectionPage\",\n    \"name\": \"\u751f\u91ab\u5927\u5065\u5eb7\u7522\u696d\u65e5\u5831 2026-07-17\uff5cEli Lilly \u65a5\u8cc7\u91cd\u91d1\u6536\u8cfc\u8ff7\u5e7b\u85e5\u5ee0 AtaiB\",\n    \"description\": \"2026 \u5e74 07 \u6708 17 \u65e5 \u751f\u91ab\u5927\u5065\u5eb7\u7522\u696d\u65e5\u5831\uff1aEli Lilly \u65a5\u8cc7\u91cd\u91d1\u6536\u8cfc\u8ff7\u5e7b\u85e5\u5ee0 AtaiBeckley\uff0c\u80a1\u50f9\u3001Vogenx \u52a0\u5165 IPO \u6392\u968a\u884c\u5217\uff0c\u52df\u8cc7\u63a8\u9032 Phase 2 \u968e\u6bb5\u4ee3\u3002\u5171\u6536\u9304 5 \u5247\u7522\u696d\u76f8\u95dc\u65b0\u805e,\u542b\u6df1\u5ea6\u5206\u6790\u3001\u53cd\u9762\u89c0\u9ede\u8207\u77ed\u4e2d\u9577\u671f\u89c0\u5bdf\u91cd\u9ede\u3002\",\n    \"url\": \"https:\/\/witology.com.tw\/daily\/2026-07-17\",\n    \"datePublished\": \"2026-07-17\",\n    \"inLanguage\": \"zh-TW\",\n    \"publisher\": {\n      \"@type\": \"Organization\",\n      \"name\": \"\u667a\u749e\u79d1\u6280\",\n      \"logo\": {\n        \"@type\": \"ImageObject\",\n        \"url\": \"https:\/\/witology.com.tw\/logo.png\"\n      }\n    },\n    \"isPartOf\": {\n      \"@type\": \"WebSite\",\n      \"name\": \"\u667a\u749e\u79d1\u6280\",\n      \"url\": \"https:\/\/witology.com.tw\"\n    },\n    \"hasPart\": [\n      {\n        \"@type\": \"NewsArticle\",\n        \"headline\": \"Eli Lilly \u65a5\u8cc7\u91cd\u91d1\u6536\u8cfc\u8ff7\u5e7b\u85e5\u5ee0 AtaiBeckley\uff0c\u80a1\u50f9\u98c6\u6f32 33%\",\n        \"datePublished\": \"2026-07-17\",\n        \"dateModified\": \"2026-07-17\",\n        \"image\": [\n          \"https:\/\/witology.com.tw\/daily\/2026-07-17\/featured_1.png\"\n        ],\n        \"author\": {\n          \"@type\": \"Organization\",\n          \"name\": \"\u667a\u749e\u79d1\u6280\u7de8\u8f2f\u90e8\"\n        },\n        \"publisher\": {\n          \"@type\": \"Organization\",\n          \"name\": \"\u667a\u749e\u79d1\u6280\",\n          \"logo\": {\n            \"@type\": \"ImageObject\",\n            \"url\": \"https:\/\/witology.com.tw\/logo.png\"\n          }\n        },\n        \"mainEntityOfPage\": {\n          \"@type\": \"WebPage\",\n          \"@id\": \"https:\/\/witology.com.tw\/daily\/2026-07-17#article-1\"\n        },\n        \"description\": \"Eli Lilly \u5ba3\u5e03\u4ee5\u6700\u9ad8\u7d04 38 \u5104\u7f8e\u5143\u6536\u8cfc\u8ff7\u5e7b\u85e5\u958b\u767c\u5546 AtaiBeckley\uff08atai Life Sciences \u8207 Beckley Psytech \u7684\u5408\u4f75\u5be6\u9ad4\uff09\uff0c\u6b63\u5f0f\u8de8\u5165\u7cbe\u795e\u79d1\u8ff7\u5e7b\u7642\u6cd5\u8cfd\u9053\u3002\u6b64\u8209\u4ee3\u8868\u5168\u7403\u5e02\u503c\u6700\u9ad8\u85e5\u5ee0\u4e4b\u4e00\u9996\u5ea6\u5927\u898f\u6a21\u62bc\u6ce8\u88f8\u84cb\u83c7\u7d20\uff08psilocybin\uff09\u3001DMT \u7b49\u8ff7\u5e7b\u7269\u8cea\u4f5c\u70ba\u7cbe\u795e\u75be\u75c5\u6cbb\u7642\u85e5\u7269\uff0cAtaiBeckley \u80a1\u50f9\u55ae\u65e5\u66b4\u6f32\u903e 33%\u3002\u9019\u662f\u7e7c J&J ketamine\",\n        \"url\": \"https:\/\/witology.com.tw\/daily\/2026-07-17#article-1\",\n        \"isBasedOn\": \"https:\/\/finance.technews.tw\/2026\/07\/17\/lilly-enters-psychedelic-drug-race-with-up-to-3-8-billion-ataibeckley-deal\/\",\n        \"about\": [\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"Eli Lilly\",\n            \"tickerSymbol\": \"LLY\"\n          },\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"atai Life Sciences\",\n            \"tickerSymbol\": \"ATAI\"\n          },\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"Beckley Psytech\"\n          },\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"COMPASS Pathways\",\n            \"tickerSymbol\": \"CMPS\"\n          },\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"MindMed\",\n            \"tickerSymbol\": \"MNMD\"\n          },\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"Johnson & Johnson\",\n            \"tickerSymbol\": \"JNJ\"\n          }\n        ]\n      },\n      {\n        \"@type\": \"NewsArticle\",\n        \"headline\": \"Vogenx \u52a0\u5165 IPO \u6392\u968a\u884c\u5217\uff0c\u52df\u8cc7\u63a8\u9032 Phase 2 \u968e\u6bb5\u4ee3\u8b1d\u75be\u75c5\u85e5\u7269\",\n        \"datePublished\": \"2026-07-17\",\n        \"dateModified\": \"2026-07-17\",\n        \"image\": [\n          \"https:\/\/witology.com.tw\/logo.png\"\n        ],\n        \"author\": {\n          \"@type\": \"Organization\",\n          \"name\": \"\u667a\u749e\u79d1\u6280\u7de8\u8f2f\u90e8\"\n        },\n        \"publisher\": {\n          \"@type\": \"Organization\",\n          \"name\": \"\u667a\u749e\u79d1\u6280\",\n          \"logo\": {\n            \"@type\": \"ImageObject\",\n            \"url\": \"https:\/\/witology.com.tw\/logo.png\"\n          }\n        },\n        \"mainEntityOfPage\": {\n          \"@type\": \"WebPage\",\n          \"@id\": \"https:\/\/witology.com.tw\/daily\/2026-07-17#article-2\"\n        },\n        \"description\": \"\u4ee3\u8b1d\u75be\u75c5\u65b0\u5275 Vogenx \u5ba3\u5e03\u555f\u52d5 IPO \u7a0b\u5e8f\uff0c\u8a08\u756b\u900f\u904e\u4e0a\u5e02\u52df\u96c6\u8cc7\u91d1\u63a8\u9032\u5176\u6838\u5fc3\u4ee3\u8b1d\u85e5\u7269\u9032\u5165 Phase 2 \u81e8\u5e8a\u8a66\u9a57\u3002\u6b64\u8209\u53cd\u6620\u7576\u524d\u751f\u6280 IPO \u5e02\u5834\u5728 GLP-1 \u71b1\u6f6e\u5e36\u52d5\u4e0b\uff0c\u4ee3\u8b1d\u75be\u75c5\u7ba1\u7dda\u4f9d\u7136\u662f\u8cc7\u672c\u5e02\u5834\u7684\u5438\u91d1\u78c1\u9435\uff1b\u7136\u800c Vogenx \u5c1a\u8655 Phase 2 \u524d\u671f\uff0c\u8ddd\u96e2\u5546\u696d\u5316\u4ecd\u6709\u76f8\u7576\u8ddd\u96e2\uff0cIPO \u6210\u529f\u8207\u5426\u9ad8\u5ea6\u53d6\u6c7a\u65bc\u5176\u5dee\u7570\u5316\u6a5f\u5236\u662f\u5426\u8db3\u4ee5\u5728 GLP-1 \u5de8\u982d\u74b0\u4f3a\u4e0b\u7372\u5f97\u6295\u8cc7\u4eba\u8a8d\u53ef\u3002\",\n        \"url\": \"https:\/\/witology.com.tw\/daily\/2026-07-17#article-2\",\n        \"isBasedOn\": \"https:\/\/www.fiercebiotech.com\/biotech\/vogenx-joins-ipo-queue-fund-phase-2-stage-metabolic-drug\",\n        \"about\": [\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"Vogenx\"\n          },\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"Eli Lilly\",\n            \"tickerSymbol\": \"LLY\"\n          },\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"Novo Nordisk\",\n            \"tickerSymbol\": \"NVO\"\n          },\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"Structure Therapeutics\",\n            \"tickerSymbol\": \"GPCR\"\n          },\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"Altimmune\",\n            \"tickerSymbol\": \"ALT\"\n          },\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"Viking Therapeutics\",\n            \"tickerSymbol\": \"VKTX\"\n          },\n          {\n            \"@type\": \"Corporation\",\n            \"name\": \"\u667a\u64ce\u751f\u6280\",\n            \"tickerSymbol\": \"4162\"\n          }\n        ]\n      }\n    ]\n  },\n  {\n    \"@context\": \"https:\/\/schema.org\",\n    \"@type\": \"BreadcrumbList\",\n    \"itemListElement\": [\n      {\n        \"@type\": \"ListItem\",\n        \"position\": 1,\n        \"name\": \"\u9996\u9801\",\n        \"item\": \"https:\/\/witology.com.tw\"\n      },\n      {\n        \"@type\": \"ListItem\",\n        \"position\": 2,\n        \"name\": \"\u751f\u91ab\u5927\u5065\u5eb7\u7522\u696d\u65e5\u5831\",\n        \"item\": \"https:\/\/witology.com.tw\/daily\"\n      },\n      {\n        \"@type\": \"ListItem\",\n        \"position\": 3,\n        \"name\": \"2026-07-17\",\n        \"item\": \"https:\/\/witology.com.tw\/daily\/2026-07-17\"\n      }\n    ]\n  },\n  {\n    \"@context\": \"https:\/\/schema.org\",\n    \"@type\": \"FAQPage\",\n    \"mainEntity\": [\n      {\n        \"@type\": \"Question\",\n        \"name\": \"Eli Lilly \u70ba\u4ec0\u9ebc\u8981\u82b1\u8fd1 38 \u5104\u7f8e\u5143\u8cb7\u4e00\u5bb6\u8ff7\u5e7b\u85e5\u516c\u53f8\uff1f\",\n        \"acceptedAnswer\": {\n          \"@type\": \"Answer\",\n          \"text\": \"Lilly \u76ee\u524d\u56e0 GLP-1 \u85e5\u7269\u7372\u5229\u8c50\u539a\uff0c\u6b63\u7a4d\u6975\u5c0b\u627e\u4e0b\u4e00\u500b\u9ad8\u6210\u9577\u9818\u57df\uff1b\u7cbe\u795e\u79d1\u5e02\u5834\u5c24\u5176\u6182\u9b31\u75c7\u3001PTSD \u7684\u672a\u6eff\u8db3\u9700\u6c42\u9f90\u5927\uff0c\u800c\u50b3\u7d71\u85e5\u7269\u7642\u6548\u6709\u9650\uff0c\u8ff7\u5e7b\u7642\u6cd5\u7684 Phase 2 \u7de9\u89e3\u7387\u6578\u64da\u9060\u512a\u65bc\u73fe\u6709\u6a19\u6e96\u7642\u6cd5\uff0c\u4f7f\u5176\u6210\u70ba\u5177\u9ad8\u5546\u696d\u6f5b\u529b\u7684\u5dee\u7570\u5316\u8ced\u6ce8\u3002\"\n        }\n      },\n      {\n        \"@type\": \"Question\",\n        \"name\": \"\u8ff7\u5e7b\u85e5\u7642\u6cd5\u771f\u7684\u5408\u6cd5\u55ce\uff1fFDA \u6703\u6279\u51c6\u55ce\uff1f\",\n        \"acceptedAnswer\": {\n          \"@type\": \"Answer\",\n          \"text\": \"FDA \u5df2\u7d66\u4e88\u88f8\u84cb\u83c7\u7d20\u300c\u7a81\u7834\u6027\u7642\u6cd5\u300d\u8a8d\u5b9a\uff0c\u4f46\u5c1a\u672a\u6279\u51c6\u4efb\u4f55\u88f8\u84cb\u83c7\u7d20\u65b0\u85e5\uff1b\u76ee\u524d\u6700\u5927\u7684\u6311\u6230\u662f Phase 3 \u76f2\u5316\u8a2d\u8a08\u7684\u79d1\u5b78\u56b4\u8b39\u6027\uff0c\u4ee5\u53ca\u5982\u4f55\u5728\u91ab\u7642\u5834\u57df\u898f\u7bc4\u300c\u8f14\u52a9\u5fc3\u7406\u6cbb\u7642\u300d\u6d41\u7a0b\uff0c\u76e3\u7ba1\u8def\u5f91\u4ecd\u5728\u6478\u7d22\u4e2d\u3002\"\n        }\n      },\n      {\n        \"@type\": \"Question\",\n        \"name\": \"AtaiBeckley \u80a1\u50f9\u6f32\u4e86 33%\uff0c\u5176\u4ed6\u8ff7\u5e7b\u85e5\u516c\u53f8\u4e5f\u6703\u8ddf\u8457\u53d7\u60e0\u55ce\uff1f\",\n        \"acceptedAnswer\": {\n          \"@type\": \"Answer\",\n          \"text\": \"\u77ed\u671f\u5167 COMPASS Pathways\u3001MindMed \u7b49\u540c\u8cfd\u9053\u516c\u53f8\u53ef\u671b\u53d7\u5230\u300c\u88ab\u6536\u8cfc\u9810\u671f\u300d\u5e36\u52d5\u4f30\u503c\u91cd\u65b0\u5b9a\u50f9\uff1b\u4f46\u82e5 Lilly \u7684\u4ea4\u6613\u662f\u6574\u500b\u5927\u85e5\u5ee0\u4f48\u5c40\u8ff7\u5e7b\u7642\u6cd5\u7684\u8d77\u9ede\uff0c\u5f8c\u7e8c\u7af6\u8cfc\u6f6e\u624d\u662f\u6301\u7e8c\u5229\u591a\uff0c\u5426\u5247\u677f\u584a\u6548\u61c9\u5c07\u5feb\u901f\u6d88\u9000\u3002\"\n        }\n      },\n      {\n        \"@type\": \"Question\",\n        \"name\": \"Vogenx \u7684\u4ee3\u8b1d\u85e5\u7269\u8ddf\u5e02\u9762\u4e0a\u7684 GLP-1 \u6e1b\u91cd\u85e5\u6709\u4ec0\u9ebc\u4e0d\u540c\uff1f\",\n        \"acceptedAnswer\": {\n          \"@type\": \"Answer\",\n          \"text\": \"\u76ee\u524d Vogenx \u7684\u5177\u9ad4\u4f5c\u7528\u6a5f\u5236\u5c1a\u672a\u5b8c\u6574\u516c\u958b\uff0c\u4f46\u4ee3\u8b1d\u75be\u75c5\u65b0\u5275\u901a\u5e38\u4ee5\u300c\u975e GLP-1 \u8def\u5f91\u300d\uff08\u5982 FGF21\u3001ACC \u6291\u5236\u5291\u3001mitochondria \u4ee3\u8b1d\u8abf\u7bc0\uff09\u6216\u300c\u53e3\u670d\u5291\u578b\u512a\u52e2\u300d\u4f5c\u70ba\u5dee\u7570\u5316\u8ce3\u9ede\uff0c\u8207 Lilly\/Novo Nordisk \u7684\u6ce8\u5c04\u578b GLP-1 \u5f62\u6210\u4e92\u88dc\u800c\u975e\u6b63\u9762\u7af6\u722d\u3002\"\n        }\n      },\n      {\n        \"@type\": \"Question\",\n        \"name\": \"\u73fe\u5728\u9019\u500b\u6642\u9593\u9ede IPO \u5c0d Vogenx \u4f86\u8aaa\u662f\u597d\u6642\u6a5f\u55ce\uff1f\",\n        \"acceptedAnswer\": {\n          \"@type\": \"Answer\",\n          \"text\": \"\u4ee3\u8b1d\u75be\u75c5\u6982\u5ff5\u80a1\u4f30\u503c\u6ea2\u50f9\u5728 2024\u20132025 \u5e74\u4ecd\u76f8\u5c0d\u9ad8\u4f4d\uff0c\u8d95\u5728 Phase 2 \u6578\u64da\u51fa\u7210\u524d\u4e0a\u5e02\u53ef\u9396\u5b9a\u8f03\u9ad8\u4f30\u503c\uff1b\u4f46\u82e5 IPO \u5f8c\u6578\u64da\u4e0d\u5982\u9810\u671f\uff0c\u80a1\u50f9\u4fee\u6b63\u5e45\u5ea6\u901a\u5e38\u76f8\u7576\u5287\u70c8\uff0c\u6295\u8cc7\u4eba\u9700\u7559\u610f Phase 2 \u6578\u64da\u6642\u7a0b\u5e36\u4f86\u7684\u9ad8\u6ce2\u52d5\u98a8\u96aa\u3002\"\n        }\n      },\n      {\n        \"@type\": \"Question\",\n        \"name\": \"\u9019\u5247\u65b0\u805e\u5c0d\u53f0\u7063\u4ee3\u8b1d\u75be\u75c5\u76f8\u95dc\u751f\u6280\u80a1\u6709\u5f71\u97ff\u55ce\uff1f\",\n        \"acceptedAnswer\": {\n          \"@type\": \"Answer\",\n          \"text\": \"\u77ed\u671f\u76f4\u63a5\u5f71\u97ff\u6709\u9650\uff0c\u4f46\u570b\u969b\u4ee3\u8b1d\u85e5\u7269\u8cfd\u9053\u6301\u7e8c\u71b1\u7d61\uff0c\u6709\u52a9\u65bc\u7dad\u6301\u5e02\u5834\u5c0d\u53f0\u7063\u4ee3\u8b1d\/\u7cd6\u5c3f\u75c5\u76f8\u95dc\u751f\u6280\u516c\u53f8\uff08\u5982\u7814\u767c NASH \u6216\u7cd6\u5c3f\u75c5\u85e5\u7269\u7684\u672c\u571f\u65b0\u5275\uff09\u7684\u95dc\u6ce8\u5ea6\u8207\u8a55\u50f9\u57fa\u6e96\u3002\"\n        }\n      }\n    ]\n  }\n]","daily_standalone_url":"","footnotes":""},"class_list":["post-8394","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/witology.com.tw\/en\/wp-json\/wp\/v2\/pages\/8394","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/witology.com.tw\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/witology.com.tw\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/witology.com.tw\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/witology.com.tw\/en\/wp-json\/wp\/v2\/comments?post=8394"}],"version-history":[{"count":0,"href":"https:\/\/witology.com.tw\/en\/wp-json\/wp\/v2\/pages\/8394\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/witology.com.tw\/en\/wp-json\/wp\/v2\/pages\/7356"}],"wp:attachment":[{"href":"https:\/\/witology.com.tw\/en\/wp-json\/wp\/v2\/media?parent=8394"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}